SCP
RIGL icon

Sender Company & Partners’s Rigel Pharmaceuticals RIGL Stock Holding History

Sender Company & Partners’s Portfolio RIGL Stock Details RIGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-19,546
Closed -$518K – 91
2021
Q4 		$518K Buy
+19,546
New +$590K 0.27% 74

Other funds holding RIGL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Sender Company & Partners's RIGL Position: Q1 2022 in Review

Sender Company & Partners sold out of Rigel Pharmaceuticals (RIGL) in Q1 2022, closing a stake of 19,546 shares — an estimated $518K sold.

Sender Company & Partners first reported a position in RIGL in Q4 2021 and held it in 1 quarter. The position peaked at $518K in Q4 2021. 163 funds tracked by Wall St. Rank hold RIGL as of Q1 2022.

  • Sender Company & Partners reported no remaining Rigel Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
  • Sender Company & Partners sold 19,546 Rigel Pharmaceuticals shares in Q1 2022, an estimated $518K.
  • Sender Company & Partners first reported a position in Rigel Pharmaceuticals in Q4 2021 and held it in 1 quarter.
  • Sender Company & Partners's Rigel Pharmaceuticals position peaked at $518K in Q4 2021.
  • 163 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q1 2022.

Based on Sender Company & Partners's 13F filing for Q1 2022, filed 17 May 2022.